Clinical Trials Browser

Nasopharyngeal Neoplasms

Rectal Neoplasms

Carcinoma, Hepatocellular

Colorectal Neoplasms

Lymphoma, Large B-Cell, Diffuse

Colorectal Neoplasms

Pancreatic Neoplasms

Carcinoma, Non-Small-Cell Lung

Gynecological Cancer

Carcinoma, Digestive System Diseases, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Stomach Neoplasms

Osteosarcoma

Squamous Cell Carcinoma of Head and Neck

Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma

Pancreatic Adenocarcinoma Metastatic

Lung Neoplasms

Neoplasm Metastasis, Paraganglioma, Extra-Adrenal, Pheochromocytoma

Advanced Solid Tumor

Breast Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

Urinary Bladder Neoplasms

Carcinoma, Non-Small-Cell Lung

Breast Neoplasm Female

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Colorectal Neoplasms

Neoplasms by Histologic Type, Lymphoma, Large B-Cell, Diffuse

Esophageal Squamous Cell Carcinoma

Thyroid Neoplasms

Uterine Cervical Neoplasms

Clinical Trials

ALTER-HN005

SPARC

JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure

LARC-nCR01

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC

PAAG

Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer

ALTER-GO-020

EXPLORING

PROMIS

Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC

Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer

RCT-PAAG

A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody

The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

Penpulimab in Maintenance Therapy in Lymphoma

Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer

A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer

AP

ALTER-C003

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Anlotinib or Penpulimab in Combination With RAI for DTC

AK105 Combined With Anlotinib in Patients With Cervical Cancer